Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

Paradoxically, many of the common treatment regimens for type 2 diabetes actually cause weight gain.

Treatment with liraglutide in LEAD(TM) 4 also led to a statistically significant decrease in blood pressure as seen in three of the other LEAD(TM) studies: reductions of 6.71 mmHg and 5.65 mmHg with liraglutide 1.2 mg and 1.8 mg, respectively, were observed compared to a decrease of 1.11 mmHg in the comparator group.

Beta cell function, as assessed by multiple parameters (HOMA, C-peptide and proinsulin to insulin ratio), was also significantly improved in subjects who received liraglutide versus the comparator group. Beta cell function is an important measure of disease progression in type 2 diabetes.

LEAD(TM) 4 is the last of the five phase 3a LEAD(TM) (Liraglutide Effect and Action in Diabetes) studies to be presented.

"The complete LEAD(TM) clinical trials program provides convincing evidence that liraglutide represents an effective new treatment approach for type 2 diabetes," said Dr. Bernard Zinman, Professor of Medicine, University of Toronto and Director of the Diabetes Centre Mount Sinai Hospital, Toronto, Canada. "In this clinical trial program, liraglutide offers effective glucose lowering as monotherapy or as an add on to other oral antidiabetic therapies while also consistently lowering weight and blood pressure and enhancing beta-cell function."

About the study

The LEAD(TM) 4 study was a 26-week randomized trial that compared the efficacy and safety of two different doses of liraglutide (1.2 mg and 1.8 mg, QD) to placebo, all added to metformin 2 g (1 g, BID) and rosiglitazone 8 mg (4 mg, BID). The trial included 533 subjects with a mean age of 55.1 years, mean body mass index of 33.5 kg/m2, and mean HbA1c of 8.3. All subjects were previously treated with one or more OADs and received run-in rosiglitazone and metformin therapy before being randomized to liraglutide or placebo.


'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
(Date:8/3/2015)... WARRINGTON, Pa. , Aug. 3, 2015 /PRNewswire/ ... a specialty biotechnology company focused on developing aerosolized ... a live teleconference and webcast at 8:30 a.m. Eastern ... time management will discuss the 2015 second quarter ... The company will issue a press release announcing ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2
... Perceptive Informatics, the industry,s leading eClinical solutions provider ... PRXL ), today announced the results ... entitled "Optimizing Adaptive Trial Designs: Using Simulation ... by Perceptive Informatics with partner Cytel Inc., a ...
... Pharmaceuticals announced today positive results from its clinical ... Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.Prednisporin(TM) ... profile (no increase in intra-ocular pressure) than PredForte(TM), ... dose of prednisolone acetate, in patients treated for ...
Cached Medicine Technology:Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 2Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 3Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 4Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 5Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 2Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
(Date:8/4/2015)... ... 2015 , ... Updated enrollment data on the top U.S. health plans, as ... at http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. ... charts on the website’s “Data” section include:, , Top 25 ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... 20 finalists for America’s Favorite Veterinarian. The contest is put on by the ... committee from 500 nominees. Nominees were evaluated on community involvement, ethical behavior, passion ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3
... Increases 32% to $14.2 Million ... Sets Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, ... products and services, today reported financial results for the,fourth quarter ... was $14.2 million, up 32.4% from $10.7 million reported in ...
... exhalations hint at wide range of conditions , , ... that uses laser light to sample a person,s breath ... number of diseases, a U.S. study says. , This ... one day help doctors screen patients for diseases such ...
... drugs is a worry, study says, , , MONDAY, Feb. 25 ... advanced dementia are given antibiotics in the last two weeks ... is whether or not that therapy has any benefits, such ... And, of concern are the risks associated with antibiotic use, ...
... Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a California based ... to $100M dollars in face value, of which ... ... CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife ...
... A sophisticated robotic dog could be a good companion ... living pet, a new Saint Louis University study suggests. ... homes interacted with Sparky, a living, medium-sized gentle mutt, ... that looks like a three-dimensional cartoon. , The most ...
... Metalsmith Michael Aram,will lend his support to another noteworthy ... doors to his flagship store on March,13th for a special ... New Delhi based charity that was,established in 1994, at a ... Foundation has committed itself to raising awareness on and,preventing the ...
Cached Medicine News:Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Laser Screen Detects Diseases in Breath 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds 2
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
Penfield Watchmaker Forceps. Tip width 0.9 mm....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: